Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$651.0M
41M shares
52-week range
$8.65 – $16.11
94% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
AngioDynamics Inc is a dynamic, diversified medical technology company committed to expanding treatment options and improving patient outcomes and quality of life by designing, manufacturing, and selling products and technologies that aid clinicians in the treatment of patients with cardiovascular disease and cancer diagnoses. The company's execution plan is built on R&D, clinical and regulatory pathway expansion, and customer-centric sales performance. The company's product offerings fall within two segments, Med Tech and Med Device. Med Tech includes Auryon and Thrombectomy, while Med Device has Peripheral Products (Interventional Devices), Ports, and Microwave Ablation. Geographically operates in the USA and Other countries; maximum revenue from the USA.
www.angiodynamics.comNo one on the platform currently holds ANGO.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 803,283 | $9.1M |
No one on the platform has traded ANGO yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$ANGO i see these products used on a regular basis. Superior to competitive products. Cheap at these prices. Will be 2-3x or acquired by 2030. 🔮
View on StockTwits ↗$ANGO Pt 20$+ this is way too cheap down at this prices??
View on StockTwits ↗🚀 Weekly Results (July 13–17) Strong performance again this week. ⭐ Top Trades: $ZNTL +10.1% $CNMD +9.1% $DINO +8.8% $TRVI +8.7% $ANGO +7.4% 📊 Consistent gains across the board. Discipline. Strategy. Results.
View on StockTwits ↗$ANGO Angiodynamics reported fiscal Q4 net sales of $86.6M, up 8% year over year and ahead of estimates. The growth is coming from its Med Tech segment, where sales rose 16.7% and NanoKnife jumped 64.5%. That mix shift lifted gross margin to 54%. For fiscal 2027, management guided to Med Tech growth of 12-15%. One sell-side firm reiterated its Buy rating and raised its price target to $19 from $16. https://prismmarketview.com/companies/angiodynamics-inc/#about
View on StockTwits ↗$ANGO would not be surprised in next few years it gets bought by boston scientific or medtronic
View on StockTwits ↗$ANGO they generated positive free cash flow no debt this thing is a gem
View on StockTwits ↗$ANGO more payer access coming for nano knife and auryon is best in class for product line segment.. this should be at 40-45
View on StockTwits ↗$ANGO $XBI $IWM $IHI been trying to give you the keys to the kingdom
View on StockTwits ↗$ANGO delivered a solid Q4 beat with revenue of $86.6M versus $80.4M expected, while the loss came in better than estimates at $0.07 per share. FY27 guidance calls for $336M-$341M in sales, with Med Tech growth expected at 12-15%. The story still comes down to execution, but the growth engine is showing signs of improving.
View on StockTwits ↗$ANGO delivered a solid Q4 beat with revenue of $86.6M versus $80.4M expected, while the loss came in better than estimates at $0.07 per share. FY27 guidance calls for $336M-$341M in sales, with Med Tech growth expected at 12-15%. The story still comes down to execution, but the growth engine is showing signs of improving.
View on StockTwits ↗$ANGO reported -0.07 EPS and 86.61 revenue for Q4. http://www.estimize.com/intro/ango?chart=historical&metric_name=eps&utm_content=ANGO&utm
View on StockTwits ↗https://www.marketbeat.com/earnings/reports/2026-7-14-angiodynamics-inc-stock/ $ANGO AngioDynamics Earnings Transcript
View on StockTwits ↗$ANGO (+3.7% pre) AngioDynamics: Fiscal Q4 Earnings Snapshot https://ooc.bz/l/107709
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $337M | +7.4% | $-0.27 | $-0.36–$-0.17 | — | 2 |
| 2028 | $355M | +5.3% | $-0.04 | $-0.05–$-0.04 | — | 2 |
| 2029 | $375M | +5.7% | $0.22 | $0.11–$0.33 | 71.1× | 2 |
| 2030 | $398M | +5.9% | $0.34 | $0.34–$0.34 | 46.0× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-14 | $-0.11 | $-0.07 | +36.4% |
| 2026-04-02 | $-0.11 | $-0.07 | +36.4% |
| 2026-01-06 | $-0.10 | $-0.15 | -50.0% |
| 2025-10-02 | $-0.14 | $-0.10 | +28.6% |
| 2025-07-15 | $-0.13 | $-0.03 | +76.9% |
| 2025-04-02 | $-0.13 | $0.03 | +123.1% |
| 2025-01-08 | $-0.11 | $-0.04 | +63.6% |
| 2024-10-03 | $-0.15 |
| $-0.11 |
| +26.7% |
| $321M |
| — |
| OCGNOcugen, Inc. | $1.35 | -3.57% | $458M | — |
| OMEROmeros Corporation | $17.35 | +26.55% | $1.3B | — |
Source: Financial Modeling Prep · peers by sector/industry